571-267-7007

Tom Irving, a Senior Partner of The Marbury Law Group, has more than 47 years of experience in intellectual property law.  His U.S. pharmaceutical practice includes America Invents Act (AIA) post-grant proceedings, due diligence, counseling (particularly on strategy and tactics), patent prosecution, reissue, and reexamination. In addition to advising on procuring strong U.S. patents, Tom counsels clients on a wide range of pharmaceutical and life sciences matters, including pre-litigation, Orange Book listings of patents covering FDA-approved drugs and methods of use, infringement issues, enforceability, supplemental examination, and validity analysis. He has served as lead counsel in numerous patent interferences, reissues, reexaminations, and AIA post-grant proceedings, as well as an expert witness in patent litigation.

Tom’s current practice is heavy on due diligence analysis, particularly for innovative targets and has driven deals where the target garnered more than one billion dollars, as well as for innovative suitors, AIA post-grant proceedings, and how to evaluate and enhance the strength of U.S. patents in the pharmaceutical space to be listed in the Orange Book and strengthened to withstand PTAB post-grant challenges and district court litigation. Tom has directed the preparation of highly complex IPRs, which worked out well for the innovative pharma patent owner. Tom also focuses on 35 U.S.C. §112(f), supplemental examination, writing claims likely to be infringed, and Sanofi v. Watson-type claims, all of which he considers to be under-utilized.

Tom has been extensively involved in counseling, due diligence, prosecution and prelitigation matters involving major drugs such as Kalydeco®, Orkambi®, Aloxi®, Tecfidera®, Lorcaserin®,Pulmicort®, Respules®, Taxotere®, Eloxatin®, Lantus®, Crestor®, Targretin®, Brilinta®, Halaven®,Allegra®, Apidra®, Epiduo Gel®, Rilutek®, Ramipril®, Jakafi®, Duexis®, Viracept®, KEVEYIS®, and, prior to FDA approval,  other drugs such as Rimonabant®, VX-661, and HMPL 0004®. He successfully reissued the patent for the low molecular weight heparin drug, Lovenox®, a blockbuster product.

For more than 25 years, Tom served as principal teacher of the now defunct Patent Resources Group (PRG)Chemical Patent Practice course, a comprehensive three-day course on U.S. chemical and life science patent law taught twice a year, and he coauthored the multi-volume treatise used in the course. He originated PRG’s Orange Book and Due Diligence courses, which helped prepare patent owners, through effective application drafting and prosecution, to withstand the rigors of AIA’s inter partes review (IPR) and post-grant review (PGR), as well as patent litigation. He presents analyses of U.S. Court of Appeals for the Federal Circuit and Patent Trial and Appeal Board (PTAB) decisions for many state bar association groups and national trade and bar association meetings, such as Intellectual Property Owners Association, American Intellectual Property Law Association (AIPLA), North Carolina and South Carolina Bar Associations, Ohio Bar Association, Texas Bar Association, CAIL in Plano Texas, and American Bar Association. Tom has lectured at many law schools, such as Harvard, Howard, Emory, Ave Maria, the University of Utah, and BYU in the United States and also law schools in China, and at the Patent Office of the State Intellectual Property Office (SIPO) of the People’s Republic of China. He has participated in well more than 150 Strafford Webinars on U.S. patent law topics, including several that dealt with 35 U.S.C. § 112(f), Sanofi v. Watson-type claims, supplemental examination, inducement to infringe, claim construction, enablement, written description, claim definiteness, REMS patents, CCPA cases, and AIA post-grant proceedings.  Over his 47 years, Tom has trained literally thousands of patent professionals in the U.S. and abroad.

Tom has been recognized by Intellectual Asset Management as a global IP leader and leading patent prosecutor in the D.C. metro area, as well as nationally for post-grant procedures. The Legal 500 U.S. has recognized him for patent portfolio management and licensing, and he has been ranked as a patent “IP Star” by Managing Intellectual Property (MIP) since 2016. Tom was inducted into the LMG Life Sciences Hall of Fame and recognized as the Patent Strategy & Management Attorney of the Year for the District of Columbia. In 2022, the American Intellectual Property Law Association (AIPLA) declared him a “Titan of the IP Bar” and the Bar Association of D.C. named him Patent Prosecutor of the Year.  Tom is very proud that just this year, the Howard Law School gave him a Lifetime Achievement Award for IP Social Justice.  Tom is deeply committed to DEI, and particularly seeks to advance the interests of women in patent law, including minority women in patent law. That contribution was recognized by the North Carolina Bar Association in March 2023.

Disclaimer